1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow COVID-19 rebound: new trials by email Literature Review of COVID-19 rebound trials Research Report on COVID-19 rebound
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir nirmatrelvir, ritonavir, placebo for nirmatrelvir - COVID-19 | Phase 2 | Completed | Pfizer | 436 | 2022-10-19 | 2024-10-08 |
COVID-19 (1)
Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Ritonavir (1) · nirmatrelvir (1)
Pfizer (1)
Canada (1) · Greece (1) · Italy (1) · Taiwan (1) · United States (1)